Priors rates this Uncertain — 62 out of 100, updated weekly. It is genuinely uncertain. On the claim that onasemnogene abeparvovec produces lower rates of unsatisfactory clinical response and fewer supportive care needs than nusinersen as first-line therapy in SMA type 1, its four-agent AI review panel weighs 4 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Gene Therapy Neuromuscular Disease review.